RCUS Q4 2021 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$354M+3636.7% YoY

Gross Profit

$354M100.0% margin

Operating Income

$281M79.3% margin

Net Income

$279M78.8% margin

EPS (Diluted)

$3.71

QoQ Revenue Growth

+3647.0%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$71M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$750M

Stockholders' Equity

$841M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$354M	$9M	+3636.7%
Gross Profit	$354M	$9M	+3636.7%
Operating Income	$281M	-$52M	+640.8%
Net Income	$279M	-$52M	+638.8%

Revenue Segments

Gilead Access Rights

$8M100%